Immunome Stock Analysis

Immunome Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Immunome was currently reported as 4.97. The company recorded a loss per share of 7.94. Immunome had not issued any dividends in recent years. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. To learn more about Immunome call Purnanand Sarma at 610 321 3700 or check out https://immunome.com.

Immunome Investment Alerts

Immunome Upcoming and Recent Events

Immunome Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 656 M.

Technical Drivers

As of the 1st of February, Immunome retains the Market Risk Adjusted Performance of (0.11), risk adjusted performance of (0.01), and Standard Deviation of 5.12. Immunome technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Immunome variance and potential upside to decide if Immunome is priced fairly, providing market reflects its last-minute price of 10.51 per share. Given that Immunome has information ratio of (0.04), we strongly advise you to confirm Immunome's regular market performance to make sure the company can sustain itself at a future point.

Immunome Price Movement Analysis

Immunome Insider Trading Activities

Immunome Outstanding Bonds

Immunome Predictive Daily Indicators

Immunome Forecast Models

Immunome's time-series forecasting models are one of many Immunome's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunome's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunome prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunome. By using and applying Immunome Stock analysis, traders can create a robust methodology for identifying Immunome entry and exit points for their positions.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.